Doré B T, Momparler R L
Departement de Pharmacologie, Université de Montréal, Québec, Canada.
Anticancer Drugs. 1992 Jun;3(3):281-7. doi: 10.1097/00001813-199206000-00012.
The antineoplastic effects of 5-aza-2'-deoxycytidine (5-AZA-CdR) and interferon-alpha (IFN-alpha) on human HL-60 myeloid leukemic cells were investigated. 5-AZA-CdR and IFN-alpha in combination produced a greater inhibition of DNA synthesis and cell growth than either agent alone. The co-treatment produced a synergistic reduction in the clonogenicity of the HL-60 leukemic cells. In addition, this combination also produced a greater reduction in mRNA expression for c-myc than each agent alone. This antileukemic action produced by 5-AZA-CdR and IFN-alpha in combination correlated with the increase in induction of differentiation of the HL-60 leukemic cells. These results suggest that 5-AZA-CdR and IFN-alpha in combination produces an enhancement of their antineoplastic action on HL-60 human myeloid leukemic cells.
研究了5-氮杂-2'-脱氧胞苷（5-AZA-CdR）和α-干扰素（IFN-α）对人HL-60髓系白血病细胞的抗肿瘤作用。5-AZA-CdR与IFN-α联合使用比单独使用任何一种药物对DNA合成和细胞生长的抑制作用更强。联合治疗使HL-60白血病细胞的克隆形成能力协同降低。此外，这种联合用药对c-myc mRNA表达的降低幅度也大于单独使用每种药物时。5-AZA-CdR与IFN-α联合产生的这种抗白血病作用与HL-60白血病细胞诱导分化增加相关。这些结果表明，5-AZA-CdR与IFN-α联合使用可增强它们对人HL-60髓系白血病细胞的抗肿瘤作用。
